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Abstract 
In view of the promising antimalarial activity of fosmidomycin or its N-acetyl homologue 
FR900098, the objective of this work was to investigate the influence of aromatic substituents 
in the alpha position of the phosphonate moiety. The envisaged analogues were prepared 
using a linear route involving a 3-aryl-3-phosphoryl propanal intermediate. The activities of 
all compounds were evaluated on E. coli 1-deoxy-D-xylulose 5-phosphate reductoisomerase 
and against two Plasmodium falciparum strains. Compared with fosmidomycin, several 
analogues displayed enhanced activity towards the P. falciparum strains. Compound 1e with a 
3,4-dichlorophenyl substitution in the α-position of fosmidomycin emerged as the most potent 
analogue of this series. It is approximately three times more potent in inhibiting the growth of 
P. falciparum than FR900098, the most potent representative of this class reported so far.  
 
 
Malaria is estimated to kill more than one million people annually and possibly as many as 
three million, with most of the deaths among children under age six living in sub-Saharan 
Africa. As a result of the resurgence of malaria and increased resistance to prevalent anti-
malarials such as chloroquine, there is an urgent need for new efficient chemotherapeutics 
against this disease.1
[Figure 1] 
 Drug development has shifted toward targeting specific proteins that are 
unique and critical for cellular growth and survival of the parasite.2,3 Recently, the presence of 
a mevalonate-independent pathway for isoprenoid biosynthesis in P. falciparum was 
discovered.4,5 1-Deoxy-D-xylulose 5-phosphate (DOXP) reductoisomerase plays an essential 
role in this non-mevalonate pathway, which is absent in humans. Previous studies 
demonstrated that fosmidomycin exerts potent antimalarial activity by inhibition of DOXP 
reductoisomerase (DXR), the second enzyme in the reaction cascade.6,7 In recent clinical trials 
conducted in Gabon and Thailand, fosmidomycin proved to be efficient in the treatment of 
patients suffering from acute, uncomplicated P. falciparum malaria.8,9 Fosmidomycin has the 
advantage to be remarkably nontoxic and to exhibit activity against multiresistant  parasite 
strains. Limitations are the short plasma half-life and the moderate resorption rate.1 The acetyl 
derivative of fosmidomycin, FR900098, was shown to be approximately twice as active 
against P. falciparum in vitro as well as in a P. vinckei mouse model.  
Fosmidomycin also represents a valuable lead for further modification. In order to study the 
structure-activity relationships, hydroxamic moiety modifications, including benzoxazolone 
and oxazolopyridinone functionaltities, have been reported.10 Also, the phosphonate moiety 
has been altered to produce prodrugs with improved oral bioavailability.11,12,13  
Interestingly, modifications addressing the three carbon spacer are scarce. The objective of 
this work was to synthesize a series of fosmidomycin or FR900098 analogues containing a 
phenyl moiety in the α-position. To sort out the influence of lipophilicity and electronic 
properties of this phenyl moiety, substituents were introduced according to Topliss’ 
methodology.14 Briefly, in this methodology an operational scheme is used to quickly identify 
the optimum substitution on a benzene ring for maximizing drug potency by virtue of 
resulting changes in hydrophobic, electronic and steric effects. 
Retrosynthetic analysis toward the synthesis of the desired analogues is depicted in Scheme 1. 
3-Aryl substituted 3-phosphoryl propanal was anticipated to be a convenient precursor. 
[Scheme 1] 
Two synthetic pathways toward this aldehyde synthon were explored (Scheme 2). The first 
route started from allyl bromide which upon Arbusow reaction with the appropriate diethyl 
benzylphosphonate in the presence of n-BuLi, afforded 4a,b in 97 and 33 % yield.15 
Oxidation of 4a,b to the vicinal cis-diol, followed by sodium periodate cleavage gave 
aldehydes 7a,b. 
[Scheme 2] 
When the desired benzylphosphonate was not commercially available, an alternative strategy 
to prepare the desired aldehydes was followed.16 A 1,4-addition of triethyl phosphite to the 
appropriately substituted cinnamaldehyde in the presence of phenol gave the acetals 6c-e in 
70-85 % yield. Subsequent deprotection afforded in 76-83 % yield the corresponding 
aldehydes, which were stable enough to be purified by flash chromatography. If necessary, 
substituted cinnamaldehydes were synthesized. Several procedures are described in the 
literature. In our hands a palladium-catalyzed synthesis from acrolein diethyl acetal and the 
corresponding aryl iodide was very efficient.17 
[Scheme 3]  
The remainder of the synthesis is depicted in Scheme 3. Treatment of 7a-e with O-
benzylhydroxylamine yielded (67-92 %) oximes 8a-e, which were reduced with sodium 
cyanoborohydride to produce benzyloxyamines 9a-e in 91-96 % yield. Subsequent acylation 
afforded 10c,d,e and 11a-e in good yield. Benzyl deprotection by catalytic hydrogenation 
gave 12c,e and 13a-e, which occurred as mixtures of two hydroxamic acid isomers (syn and 
anti). Generally, hydrogenolysis of the benzyl group was accompanied by partial 
deoxygenation, while attempted deprotection of compound 10d using hydrogenolysis or BCl3 
led to loss of the formyl moiety. Compounds 12c,e and 13a-e were finally deprotected with 
TMSBr in CH2Cl2 to afford pure 1c,e and 2a-e after purification by reversed phase HPLC.18 
All final compounds were tested for inhibition of recombinant E. coli DXR. The assay used 
was based on the photometric measurement of the NADPH turnover associated with the DXR 
catalysed reaction.7 In addition, the in vitro antimalarial activity of the compounds was 
determined. Intraerythrocytic stages of the P. falciparum strains D2d or 3D7 were incubated 
with serial dilutions of the drugs and the viability of the parasites assessed by their ability to 
incorporate [3H]hypoxanthine into DNA.19 Fosmidomycin and FR900098 were included as 
reference compounds. 
Compared with fosmidomycin, all investigated analogues were weaker inhibitors of E. coli 
DXR (Table 1). Analysis of the order of DXR inhibitory potency in the N-acetyl series 2a-e  
(2d ≈ 2e > 2a > 2b > 2c) indicates that the activity is mainly +σ-controlled (4-Cl ≈ 3,4-diCl > 
H > 4-Me > 4-MeO). Although generally weaker than fosmidomycin in inhibiting E. coli 
DXR, all α-substituted analogues studied However, several of them significantly surpassed 
the activity of fosmidomycin to inhibit the parasite growth. Remarkably, the formyl analogues 
1c and 1e consistently outperformed the acetyl derivatives 2c and 2e, both in the enzyme and 
the parasite growth inhibition assay. An opposite trend was observed for the 
fosmidomycin/FR900098 couple in the parasite growth inhibition assay, in accordance with 
previous studies.4 Interestingly, a worthwhile correlation was observed between the IC50 
values of 1c, 1e and 2a-e for DXR and their IC50 for the malaria strains, indicating that E. coli 
DXR inhibition is a useful predictor to estimate the in vitro antimalarial activity. However, 
this correlation only seems to hold when considering a set of closely related analogues. 
Indeed, while fosmidomycin is clearly superior to the α-substituted analogues as DXR 
inhibitor, it is less active in inhibiting P. falciparum growth.  
Compound 1e emerged as the most promising analogue of this series. Its in vitro antimalarial 
activity indicated that it is twelve-fold more active than fosmidomycin and also exceeds the 
activity of FR900098, the most potent analogue known to date. Apparently, the lipophilic and 
electronegative properties of the 3,4-dichloro-substitution pattern selectively favour the 
interaction with the P. falciparum DXR homologue. Alternatively, the aromatic ring in the α-
position may improve the capacity of the compounds to enter the parasite cells.  
In summary, a practical method for the synthesis of α-aryl substituted fosmidomycin 
analogues was developed. Several analogues were superior to fosmidomycin in inhibiting the 
growth of malaria parasites. 
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compound R R1 R2 IC50 (μM) E. coli DXR1 
IC50 (μM) 
Dd2 
IC50 (μM)  
3D7 
2a CH3 H H 0.311 ± 0.120 0.35 0.55 
2b CH3 Me H 0.396 ± 0.061 0.22 0.95 
1c H OMe H 0.156 ± 0.043 0.20 0.36 
2c CH3 OMe H 0.459 ± 0.109 0.27 0.85 
2d CH3 Cl H 0.099 ± 0.026 0.095 0.35 
1e H Cl Cl 0.059 ± 0.020 0.028 0.090 
2e CH3 Cl Cl 0.119 ± 0.019 0.090 0.25 
fosmidomycin    0.030 ± 0.008 0.36 1.1 
FR900098    0.030 ± 0.008 0.18 0.32 
 1Mean values ±  standard deviation of 3 to 5 independent measurements  
 
Table 1. IC50 values against recombinant E. coli DXR and Dd2 and 3D7 P. falciparum strains 
 
Legends 
 
Figure 1. Structures of fosmidomycin, FR900098 and analogues under study. 
 
Scheme 1. Retrosynthetic route toward analogues 1 and 2. 
 
Scheme 2. Reagents and conditions: (a) (i) n-BuLi, THF, -50 to -70 °C, (ii) allyl bromide, -70 
°C; (b) (i) OsO4, 4-methyl-morpholine N-oxide, dioxane (ii) NaIO4;  (c) triethyl phosphite, 
phenol, 100 °C; (d) 2N HCl, rt. 
 
Scheme 3. Reagents and conditions: (a) O-benzylhydroxylamine, pyridine, EtOH, rt; (b) 
NaCNBH3, MeOH, HCl, rt;  (c) Acetyl chloride, CH2Cl2, EtN3, 0 °C or carbonyldiimidazole, 
HCOOH, CH2Cl2, rt; (d) H2, Pd/C, MeOH, rt; (e) TMSBr, CH2Cl2, rt. 
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